Second Interim Report to the Public on CERTAIN PHARMACEUTICALS AND INTERMEDIATE CHEMICALS: IDENTIFI­ CATION OF APPLICABLE 6-DIGIT HS SUBHEADINGS. .· FOR PRODUCTS ·coVERED BY THE PROPOSED URUGUAY ROUND PHARMACEUTICAL A,GREEMENT Investigation No. 332-322 USITC PUBLICATION 2500 APRIL 1992 ,f~· United States International Trade Commission . ·J, Washington, DC 20436 . ·-~}~~:; . _:, -~;<$f ·!•;. UNITED STATES INTERNATIONAL TRADE COMMISSION COMMISSIONERS Don E. Newquist, Chairman Anne E. Brunsdale, Vice Chairman David B. Rohr Carol T. Crawford Janet A. Nuzum Peter S. Watson Office of Operations Charles W. Ervin, Director Office of Industries Rohen A. Rogowsky, Director This report was prepared principally by Eli?.abcth R. Ncsbiu Project Leader Aimison Jonnard Edward Matusik David Michels James Raftery Office of Industries David Beck Office of Tariff Affairs and Trade Agreements With assistance from Paul Daniels James Gill Office ofInformation Resources Management Under the direction of John J. Gersic, Chief Energy & Chemicals Division and Edmund D. Cappuccilli, Chief Energy, Petroleum, Benzenoid Chemicals, and Rubber and Plastics Branch · Energy & Chemicals Division Additional assistance provided by Brenda Carroll and Keilh Hipp With special assistance from U.S. Customs Service Address all communications to Kenneth R. Mason, Secreta·ry to the Commission United States International Trade Commission Washington, DC 20436 PREFACE This report is the second of two interim reports to the public pertaining to Commission investigation No. 332-322, entitled Certain Pharmaceuticals and Intermediate Chemicals; Identification of Applicable 6-Digit HS Subheadings for Products Covered by the Proposed Uruguay Round Pharmaceutical Agreement. The investigation was instituted following receipt of a letter from the United States Trade Representative (USTR) on January 27, 1992, requesting that the Commission conduct an investigation under section 332(g) of the Tariff Act of 1930 (see appendix A for a copy of the USTR' s request)·. The Commission was also asked to identify each instance where there is a known difference in ~inion among countries on the classification of a product. USTR has requested the Commissioner of the U.S. Customs Service (Customs) to provide Commission staff with any necessary technical assistance. The USTR asked the Commission to submit its report by June 1, 1992. The purpose of the investigation is to provide the USTR with a rE[!port listing the 6-digit Harmonized Commodity Description and Coding System (HS) subheadings for those pharmaceuticals having an International Non-proprietary Name (INN) and certain intermediate chemical products (used primarily in the production of pharmaceuticals) to be covered under the proposed nzero-for-zeron initiative on pharmaceuticals. This initiative, currently being negotiated under the Uruguay Round market access negotiations, provides for reciprocal duty-free treatment among major trading partners for pharmaceuticals and certain intermediate chemical products. As of the date of institution of this investigation, the request from the USTR regarding this initiative covered a total of 6,085- INNs and 272 intermediate chemicals. Inasmuch as the USTR asked that the Commission make its work available to the USTR and the public on a flow basis, the Commission plans, as indicated in the Commission's notice of institution, reproduced in appendix B of this report as published in the Federal Register, to make available two interim reports to the public. Each interim report will contain a listing of the classifications completed by that phase of the investigation. These preliminary 6-digit HS classifications were derived on the basis that the chemical names provided represented separate chemically defined compounds. No public hearing will be held in connection with this investigation. However, interested parties are requested to submit written statements to the Commission regarding any discrepancies between their current classifications for the chemicals under consideration and the classifications presented by the Commission. The deadline for submissions regarding this second interim report is close of business (5;15 pm) on May 8, 1992 (see appendix B for more information) . Proof of such classification discrepancies are requested either in the form of either official rulings by the U.S. Customs Service (Customs) or copies of prior communications with Customs on this issue. The Commission will work with Customs personnel to resolve any classification discrepancies presented by interested parties. It should be noted that the classifications presented in the Commission's report(s) are not intended to be and wil_l not be binding upon the Customs Service and should not be considered formal or informal rulings or advice. i CONTENTS Preface i Tables 1. Tariff Classifications: Phannaceuticals having an INN and their corresponding HTS subheadings 1 Appendices A. Copy of the letter of request from the United States Trade Representative A-1 B. Copy of the Commission's notice of institution of investigation, as published in the Fesieral Register B-1 iii Table 1 Tariff Classifications: Pharmaceuticals having an INN and their corresponding HTS subheadings (One asterisk (*) denotes INN names for radicals and groups proposed by the World Health Organization. Two asterisks (**) indicate that either structural information was not available at time of classification or description is too general to classify.) HTS HTS subheading INN subheading INN 2924.10 ACBNBORAMIC ACID 3003.90 BUTHALITAL SODIUM * ACBTORATB 2931.60 CALCIUM SODIUM FBRRICLATB * ACISTRATB * CAMSILATB 2936.10 ACITRBTIN * CARBBSILATB 2918.21 ADAPALBNB 2931.00 CARBOPLATIN 2926.90 ALMOKALANT 2933. 71 CARMOFOR 2914. 70 AMCINAFAL 3001.20 CARPBRITIDB 2914. 70 AMCINAFIDB 2924.29 CASOKBFAMIDB ** AMINOACID 2934.10 CBFCLIDIN 2933.71 AMPHBNIDONB 2934.10 CBFDALOXIMB 2922.30 AMRUBICIN 2941.90 CBFDINIR 2933.90 AMTOLMBTIN GUACIL 2934.10 CBFBMPIDONB .... 2937.99 ANAGBSTONB 2941.90 CBFBPIMB 2933 .59 ANAGRBLIDB 2934.10 CBFBTBCOL 293'. 90 APRIKALIM 2941.90 CBFMBPIDIUM CHLORIDE 2940.00 APROSULATB SODIUM 2934.10 CBFQUINOMB 2922.49 ARAPROFBN 2934.10 CBFTBRAM * AXBTIL 2934.10 CBFUZONAM 2933.39 BARNIDIPINB 3001.90 CBLMOLBOKIN 2934.90 BBCLICONAZOLB ** CBTRORBLIX 2937.29 BBCLOMBTASONB ** CHOLINB ALFOSCBRATB 2916.31 BBMBSBTRON 2918.90 CICAPROST 2933.90 BBRTOSAMIL 2937.99 CICLBSONIDB * BBSILATB 2934.90 CICLBTANINB 2922.49 BBTAMIPRON * CICLOTATB * BBZOMIL 2931.00 CIDBFBRRON 2934.90 BIMAJCALIM 2934.90 CIFOSTODINB 2933.90 BINDARIT 2933.90 CILAZAPRILAT 2934.90 BINOSPIRONB 2933.39 CILOBRADINB 2939.90 BIORBSMBTHRIN 2933.90 CILOFUNGIN 2933 .90 BRINAZARONB 2933.29 CILUTAZOLINB 2939.90 BROVINCAMINB 2926.90 CIMATBROL 2937.21 BUDBSONIDB 2934.90 CINOXOPAZIDB * BUNAPSILATB 2914 .50 CIOTSRONBL * BUTBPRATB * CIPIONATB Table 1--Continued Tariff Classifications: Pharmaceuticals having an INN and their corresponding HTS subheadings (One asterisk (*) denotes INN names for radicals and groups proposed by the World Health Organization. Two asterisks (**) indicate that either structural information was not available at time of classification or description is too general to classify.) HTS HTS subheadinq INN _subhe_adinq INN 2933.40 CIPRBFADOL 2928.00 DBFBROXAMINB 2933.40 CIPROQUINATB 3913.90 DBFIBROTIDB 2934.90 CISCONAZOLB 2934.90 DBFLAZACORT 2930.90 CISTINBXINB 2929.90 DBFOSFAMIDB 2934.90 CITATBPINB 2939.90 DBHYDROBMBTINB 2924.21 CLANFBNUR 2914 .29 DBLANTBRONB 2941.50 CLARITHROMYCIN 2922.49 DBLAPRIL 2933 .69 CLAZURIL 2939.60 DBLBRGOTRILB 2934.90 CLBNTIAZBM 2935.00 DBLFANTRINB 2933.40 CLIMIQUALINB 2933.90 DBLFAPRAZINB 2922.29 CLIROPAMINB 2937.90 DBLMADINONB 2922.50 CLOMIFBNOXIDB 2933.90 DBLMBTACIN 2934 .,90 CLOPIDOGRBL 2934.90 DBLMOPINOL "' •• CLOSILATB 2933.90 DBLORAZBPAM •• CORTICORBLIN 2917.19 DBLOXOLONB •• CRILANOMBR 2918.90 DBLPROSTBNATB •• CROBBFATB 2903.69 DBMBRBXINB •• CROMACATB 2924.29 DBMBCARIUM BROMIDB •• CROMBSILATB 2939.90 DBMBCOLCINB •• DALFOPRISTIN 2941.30 DBMBCYCLINB •• DALTBPARIN SODIUM 2914 .29 DBMBGBSTONB •• DAJNASTATIN 2921.49 DBMBLV8RINB •• DAPOXBTINB 2928.00 DBMBXIPTILINB •• DBANIL 2933.29 DBMOCONAZOLB •• DBBROPOL 2934.90 DBMOXYTOCIN •• DBCIL 2924.29 DBNATONIUM BBNZOATB 2924.29 DBCIMBMIDB 2922.50 DBNAVBRINB 2934.90 DBCITABINB 2933.90 DBNBUFYLLINB 2933.39 DBCITROPINB 2918.90 DBNIPRIDB 2933.39 DBCLBNPBRONB 2922.50 DBNOPAMINB 2933.59 DBCLOXIZINB 2933.90 DBNPIDAZONB 2922.50 DBCOMINOL 2933.29 DBNZIMOL 2933.90 DBCOQUINATB 2933.90 DBPRAMINB 2921.19 DBCTAFLUR 2937.29 DBPRODONB 2923.90 DBDITONIUM BROMIDE 2918.90 DBPRQSTIL Table 1--Continued Tariff Classifications: Pharmaceuticals having an INN and their corresponding HTS subheadings (One asterisk (*) denotes INN names for radicals and groups proposed by the World Health Organization. Two asterisks (**) indicate that either structural information was not available at time of classification or description is too general to classify.) HTS HTS subheadine:t .. _ _lmi___ __ subheadine:t INN 2933.39 DBPTROPINB 2933.90 DBXCLAMOL 2933.40 DBQUALINIUM CHLORIDB 2933.39 DBXBTIMIDB ** DBRAMCICLANB 2934.10 DBXBTOZOLINB 2939.90 DBRPANICATB 2921.59 DBXFBNFLURAMINB 2914 .69 DBSASPIDIN 2916.39 DBXIBUPROFBN 2933.90 DBSCICLOVIR 2933.90 DBXIMAFBN 2932.90 DBSCINOLONB 2933.79 DBXINDOPROFBN 2939.90 DBSBRPIDINB 2933.39 DBXIVACAINB 2909.19 DBSFLURANB 2933.29 DBXLOFBXIDINB 2933.90 DBSGLUGASTRIN ** DBXLOXIGLUMIDB 2933.90 DBSIPRAMINB 2933.90 DBXMBDBTOMIDINB 2938.90 DBSLANOSIDB· ** I DBXNAFBNODONB w 2937.99 DBSLORBLIN 2930.90 DBXORMAPLATIN 2924.29 DBSMBTHYLMORAMIDB